Skip to main content
Equibles

Sean LeMond

Analyst

Morgan Stanley

Equibles does not estimate personal net worth.

About Sean LeMond

Sean LeMond is recorded as Analyst at Morgan Stanley. Sean LeMond has spoken on 1 earnings call across 1 company, most recently for Neurocrine Biosciences Inc on February 11, 2026. The companies whose calls Sean LeMond spoke on are classified in the Healthcare sector.

Sean LeMond on recent calls

“Just going back to the recent data you showed for Ingressa and the 80% receptor occupancy, it seems like a pretty high hurdle. So do you think you can beat that with 890 or is it really with 890 more about just expanding the population base through that long-acting profile?”
Analyst — Morgan Stanley, Neurocrine Biosciences Inc Q4 FY2025 Earnings Call ·

Affiliation history

  • Morgan Stanley

    Analyst

    Transcript header (unverified)

    Current

Company network

Recent activity